Table 4.
Univariate and multivariate analyses by cancer-specific survival rates using the Cox proportional hazards model in all patients.
| Characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | P value | Hazard ratio | 95% CI | P value | |
| Age (>60 versus ≤60) | 1.143 | 0.623–2.095 | 0.666 | |||
| Sex (female versus male) | 0.9 | 0.452–1.792 | 0.765 | |||
| Advanced T stage (pT4 versus pT2-3) | 3.452 | 1.453–8.202 | 0.005 | 3.366 | 1.010–11.214 | 0.048 |
| Advanced N stage (pN2-3 versus pN0-1) | 4.344 | 2.214–8.522 | <0.001 | 1.919 | 0.147–1.838 | 0.310 |
| Lauren classification (diffuse versus nondiffuse) | 1.532 | 0.827–2.838 | 0.175 | 0.506 | 0.928–4.204 | 0.077 |
| Lymphatic invasion (yes versus no) | 12.903 | 1.774–93.854 | 0.012 | 5.759 | 0.718–46.228 | 0.099 |
| Venous invasion (yes versus no) | 2.744 | 1.149–6.553 | 0.023 | 0.380 | 0.990–6.990 | 0.052 |
| Tumor grade (moderate–poor versus well) | 2.866 | 0.692–11.86 | 0.146 | 2.983 | 0.057–1.970 | 0.226 |
| Adjuvant chemotherapy (yes versus no) | 0.794 | 0.433–1.454 | 0.454 | |||
| LNR (>median versus ≤median) | 6.476 | 2.987–14.042 | <0.001 | 0.2662 | 1.122–12.579 | 0.031 |
| Tumoral Cav-1 expression, primary tumor (high versus low) | 0.496 | 0.153–1.605 | 0.242 | 0.3945 | 0.084–1.849 | 0.237 |
| Stromal Cav-1 expression, primary tumor (high versus low) | 1.48 | 0.756–2.897 | 0.253 | |||
| Tumoral Cav-1 expression, lymph node (high versus low) | 3.064 | 1.429–6.569 | 0.004 | 2.681 | 1.612–8.623 | 0.002 |
LNR: lymph node ratio.